Embecta Corp.

NASDAQ:EMBC

Drug Manufacturers - Specialty & Generic

Healthcare
$6.09 +0.65%

+$0.02 today

Market cap
$345.06M
Beta
0.81
P/E (TTM)
1.6
EPS (TTM)
$1.92
Dividend yield
14.79%
52W Low $2.77High $15.55

Volume 0.72M

Average 1.95M

EMBC Pre-Tax Margin

Income before tax as a percentage of revenue.

Embecta Corp.NASDAQ: EMBC

Pre-Tax Margin · Q2 FY2026 · quarter ended Mar 2026

Pre-tax margin narrows to 4.3%

Pre-tax margin was 4.3% in Q2 FY2026, down 9.5 pp from a year earlier. On a trailing-twelve-month basis it was 16.3%, up 11.2 pp year over year. Over 3 fiscal years it narrowed by 10.1 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
4.3%-18.3 pp QoQ
Last fiscal yearSep 2025
12.6%+8.7 pp YoY
LTMMar 2026
16.3%+11.2 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-9.5 pp——
1 year+8.7 pp——
3 years-10.1 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
12.6%
Year-over-year change
+8.7pp

Pre-Tax Margin vs competitors

How EMBC compares with its peers on the latest reported figures

  • EMBC's LTM Mar 2026 pre-tax margin of 16.3% is the 3rd highest of the 11 companies compared; the peer median is -56.8%.
  • Its year-over-year change of +11.2 pp is the 4th highest of 11, against a peer median of -7.4 pp.
  • Over three fiscal years its change of -10.1 pp compares with a peer median of -25.5 pp.
EMBC Competitors Peer median
Pre-Tax Margin for EMBC and competitors
Company Period LTM level YoY 3-year change
SIGASIGA Technologies, Inc.LTM Mar 202628.7% -23.0 pp-7.7 pp
CDNACareDx, IncLTM Jun 202625.1% +9.9 pp+18.1 pp
EMBCEmbecta Corp.LTM Mar 202616.3% +11.2 pp-10.1 pp
EBSEmergent BioSolutions Inc.LTM Mar 20260.5% +7.0 pp+30.7 pp
EVHEvolent Health, Inc.LTM Mar 2026-26.3% -21.8 pp-23.9 pp
MYGNMyriad Genetics, Inc.LTM Mar 2026-48.2% -33.0 pp-27.2 pp
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-65.4% +96.3 pp-189.0 pp
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-137.1% -37.0 pp-74.0 pp
PSNLPersonalis, Inc.LTM Mar 2026-148.1% -50.0 pp—
VIRVir Biotechnology, Inc.LTM Mar 2026-675.4% +2100.4 pp-685.2 pp
PRMEPrime Medicine, Inc.LTM Mar 2026-4917.6% +338.4 pp—
Peer median (excluding EMBC) -56.8%-7.4 pp-25.5 pp

Competitors are the stored peer set for EMBC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue1.17B1.13B1.12B1.12B1.08B
Cost of Revenue365M354.6M370.9M394.2M400.9M
Gross Profit800M774.9M749.9M728.9M679.5M
Gross Margin68.7%68.6%66.9%64.9%62.9%
Research & Development63M65M85.2M78.8M21.5M
Selling, General & Admin240.3M294.8M341.3M365.1M331.4M
Operating Expenses308M396.8M520.3M554.7M350.2M
Depreciation & Amortization38M31.7M32.7M42.5M51.1M
EBITDA533M334.5M245.4M199M294.7M
EBITDA Margin45.8%29.6%21.9%17.7%27.3%
Operating Income492M378.1M229.6M174.2M329.3M
Operating Margin42.2%33.5%20.5%15.5%30.5%
Interest Income00000
Interest Expense046.2M107M112.3M107.3M
Other Income / Expenses3M(121.5M)(123.9M)(130M)(193M)
Income Before Tax495M256.6M105.7M44.2M136.3M
Pre-Tax Margin42.5%22.7%9.4%3.9%12.6%
Income Tax Expense80M33M35.3M(34.1M)40.9M
Net Income414.8M223.6M70.4M78.3M95.4M
Net Margin35.6%19.8%6.3%7.0%8.8%
EPS (Basic)7.313.921.231.361.64
EPS (Diluted)7.313.891.221.341.62
Weighted Avg Shares56.8M57.06M57.24M58.43M58.31M
Weighted Avg Shares (Diluted)56.8M57.06M57.76M58.33M58.92M

Embecta Corp.

NASDAQ:EMBC

Intrinsic Alpha fair value

Locked

Current Price

$6.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.